For CLL patients, the expression of BCL-2 on T cells increases the differentiation of regulatory T cells (Tregs), the exhaustion of cytotoxic T lymphocytes (CTLs), and the levels of suppressive cytokines, such as IL-10 and TGF-β (45). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.